No Detail Found!

Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.

Author(s)
Khurshid Ahmed Khan Department of Oncology, National Oncology Research Institute, Islamabad, Pakistan
Ayesha Junaid Department of Pathology, Shifa International Hospital, Islamabad, Pakistan
Nauman Saleem Siddiqui Shifa International Hospital, Islamabad, Pakistan
Khalida Mukhtar Shifa International Hospital, Islamabad, Pakistan
Saleem Siddiqui Department of Gastroenterology and Medicine, Shifa International Hospital, Islamabad, Pakistan
Abstract
Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.
Publication Details
Page(s) 176-178
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 18, Issue: 3, Year: 2008

Request the full text from PASTIC

0

Citations

0

Downloads

54

Views